Stockholm Calls: Docs Eye New Tactics for Type 2 Diabetes at EASD
New data on tirzepatide for weight loss and potential type 2 diabetes remission as well as an update on use of dapagliflozin for heart failure will be presented at the first in-person EASD meeting for 3 years.
Medscape Medical News
source https://www.medscape.com/viewarticle/980769?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/980769?src=rss
Comments
Post a Comment